Routine

Anti-obesity pharmacotherapy

obesity drugs · Endocrine
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Pharmacological treatment of obesity as an adjunct to lifestyle, now dominated by incretin-based agents producing substantial weight loss and cardiometabolic benefit. Patient selection, titration and monitoring are key.

Red flags

  • Severe persistent vomiting or features of gastroparesis
  • Acute pancreatitis or gallbladder disease
  • Personal/family history of medullary thyroid cancer or MEN2 (GLP-1 contraindication)
  • Suicidal ideation (naltrexone/bupropion)
  • Rapid excessive weight loss or malnutrition

Assessment

Differential diagnosis

  • Hypothyroidism
  • Cushing syndrome
  • Hypothalamic/genetic obesity
  • Drug-induced weight gain
  • Oedematous states

Investigations

  • BMI and waist circumference
  • HbA1c, lipids, blood pressure and liver function
  • TSH to exclude hypothyroidism
  • Screen for obesity-related complications (sleep apnoea, MASLD)
  • Assessment of eating pattern and comorbidity

Management

  • Confirm obesity (BMI >=30, or >=27 with comorbidity) and exclude secondary causes
  • Establish structured lifestyle intervention as the foundation
  • Discuss realistic expectations, side effects and duration of therapy
  • Select agent by efficacy, comorbidity and availability
  • Start incretin therapy at low dose and titrate slowly to limit gastrointestinal effects
  • Monitor weight, metabolic parameters and tolerability
  • Review response: consider stopping/switching if <5% loss after adequate trial
  • Address gallstone, pancreatitis and (for some agents) psychiatric risks
  • Plan for weight regain on discontinuation and counsel on long-term therapy
  • Refer suitable high-BMI patients for bariatric surgery assessment

Drugs & doses

Semaglutide 0.25 mg SC weekly titrated to 2.4 mg (Wegovy)
Tirzepatide 2.5 mg SC weekly titrated to 15 mg
Liraglutide 0.6 mg SC daily titrated to 3 mg
Orlistat 120 mg PO three times daily with meals
Naltrexone/bupropion combination as an alternative

Disposition

Prescribe within weight-management pathways; refer to specialist/bariatric services for high BMI, complex comorbidity or inadequate response.

Complications & pitfalls

  • Gastrointestinal intolerance
  • Gallstones and pancreatitis
  • Muscle mass loss with rapid weight loss
  • Weight regain after stopping
  • Nutrient deficiencies

Exam pearls

  • Incretin agents require slow titration to minimise nausea and improve adherence
  • Weight tends to return after stopping, so frame treatment as long-term
  • Avoid GLP-1/GIP agents with a personal or family history of medullary thyroid carcinoma or MEN2
  • Combine pharmacotherapy with sustained lifestyle change and consider surgery at higher BMI

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.